• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fresenius Medical Care AG

    2/14/23 2:21:02 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    SC 13G 1 d465343dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 0)*

     

     

    FRESENIUS MEDICAL CARE AG & Co. KGaA

    (Name of Issuer)

    Ordinary Shares and American Depositary Shares

    (Title of Class of Securities)

    358029106

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 358029106   13G   PAGE 2 OF 4 PAGES

     

      1   

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Dodge & Cox    94-1441976

      2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  ☐        (b)  ☐

     

    N/A

      3   

      SEC USE ONLY

     

      4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California - U.S.A.

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

          5     

    SOLE VOTING POWER

     

    13,567,927 Ordinary Shares and 3,504,200 American Depositary Shares

          6   

    SHARED VOTING POWER

     

    0

          7   

    SOLE DISPOSITIVE POWER

     

    14,122,927 Ordinary Shares and 3,504,200 American Depositary Shares

          8   

    SHARED DISPOSITIVE POWER

     

    0

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,122,927 Ordinary Shares and 3,504,200 American Depositary Shares

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    N/A

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.4%

    12   

    TYPE OF REPORTING PERSON*

     

    IA

     


    Item 1(a)

    Name of Issuer:

    FRESENIUS MEDICAL CARE AG & Co. KGaA

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    Else-Kröner Strasse 1

    61352 Homburg

    Germany

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Ordinary Shares and American Depositary Shares

     

    Item 2(e)

    CUSIP Number:

    358029106

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

      (e)

    ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    14,122,927 Ordinary Shares and 3,504,200 American Depositary Shares

     

      (b)

    Percent of Class:

    5.4%

     


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    13,567,927 Ordinary Shares and 3,504,200 American Depositary Shares

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    14,122,927 Ordinary Shares and 3,504,200 American Depositary Shares

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, FRESENIUS MEDICAL CARE AG & Co. KGaA. Shares.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent

    Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose

    or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2023

     

    DODGE & COX
    By:   /S/ Katherine M. Primas
    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer
    Get the next $FMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical upgraded by BofA Securities

    BofA Securities upgraded Fresenius Medical from Underperform to Neutral

    12/2/24 8:51:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Berenberg initiated coverage on Fresenius Medical with a new price target

    Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

    11/6/24 6:26:23 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by Morgan Stanley

    Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

    1/8/24 7:47:44 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/11/25 7:34:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/5/25 10:19:53 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/5/25 6:00:31 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

    Total volume of the initial share buyback is up to EUR 1 billion over two yearsShare buyback to take place until August 10, 2027BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.

    8/11/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

    Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life SciencesProvides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registryPaves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis effo

    7/31/25 8:30:00 AM ET
    $AZTA
    $FMS
    Industrial Machinery/Components
    Technology
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

    FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

    6/17/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

    Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

    5/22/25 11:45:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

    SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

    12/7/23 11:45:52 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    View All

    Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

    Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

    3/13/24 10:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

    BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

    2/5/24 8:57:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

    Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

    7/14/23 11:34:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care